Trial Profile
A Phase II Study of AZD2171 in Hepatocellular Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2016
Price :
$35
*
At a glance
- Drugs Cediranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 13 Mar 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 20 May 2009 Actual initiation date (May 2009) added as reported by ClinicalTrials.gov.